Literature DB >> 1133736

Central versus peripheral anticholinergic activity as assessed by two in vivo procedures in mice.

J B Malick, A Barnett.   

Abstract

The activity of tertiary and quaternary anticholinergic drugs was compared in two different test procedures designed to measure cholinolytic activity in mice. The four drugs utilized were atropine sulfate, atropine methylnitrate, scopolamine hydrobromide, and scopolamine methylnitrate. The results led to the conclusion that one of these test procedures, the induction of mydriasis (increase in pupil size), primarily measures peripheral anticholinergic activity whereas the other procedure, inhibition of physostigmine lethality, primarily measures anticholinergic activity in the CNS. These two test procedures can be utilized to characterize the nature of the cholinolytic properties of prospective therapeutic drug candidates.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1133736     DOI: 10.1002/jps.2600640650

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  4 in total

1.  Xenin-25 potentiates glucose-dependent insulinotropic polypeptide action via a novel cholinergic relay mechanism.

Authors:  Burton M Wice; Songyan Wang; Dan L Crimmins; Kelly A Diggs-Andrews; Matthew C Althage; Eric L Ford; Hung Tran; Matthew Ohlendorf; Terry A Griest; Qiuling Wang; Simon J Fisher; Jack H Ladenson; Kenneth S Polonsky
Journal:  J Biol Chem       Date:  2010-04-26       Impact factor: 5.157

2.  Evaluation of the CNS properties of SCH 29851, a potential non-sedating antihistamine. 1984.

Authors:  A Barnett; L C Iorio; W Kreutner; S Tozzi; H S Ahn; A Gulbenkian
Journal:  Agents Actions       Date:  1994-12

3.  Methoscopolamine inhibition of sleep-related growth hormone secretion. Evidence for a cholinergic secretory mechanism.

Authors:  W B Mendelson; N Sitaram; R J Wyatt; J C Gillin; L S Jacobs
Journal:  J Clin Invest       Date:  1978-06       Impact factor: 14.808

4.  Evaluation of the CNS properties of SCH 29851, a potential non-sedating antihistamine.

Authors:  A Barnett; L C Iorio; W Kreutner; S Tozzi; H S Ahn; A Gulbenkian
Journal:  Agents Actions       Date:  1984-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.